- Overview:
- You could be part of a clinical study programme that helps get more information on how a new, once-weekly insulin product, helps in reducing the blood sugar compared with insulin products taken once daily.
- Staus:
- Enrolling
- Clinical Description:
- This is a global programme of clinical studies to investigate how well insulin icodec (a new, investigational long-acting insulin taken once weekly), controls blood sugar in people with diabetes. Once-weekly insulin icodec will be compared with insulins taken once daily, which are already available on the market. As part of the programme, this study will look at how well insulin icodec, taken once weekly, and insulin glargine U100 taken once daily, control blood sugar in combination with insulin aspart, in adults with type 1 diabetes.
- Target Age/Sex:
- M/F 18+ years old
- Benefits:
- You will not be charged by participating in this study.
- Study Length:
- About 8.5 months
